The changing epidemiology of healthcare-associated candidemia over three decades

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 1, 2012, Pages 45-48

  Diekema, Daniel ^a   Arbefeville, Sophie ^b   Boyken, Linda ^a   Kroeger, Jennifer ^a,c   Pfaller, Michael ^a,c,d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d JMI LABORATORIES   (United States)

Author keywords

Candidemia; Echinocandin; Epidemiology

Indexed keywords

CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNGUS IDENTIFICATION; HEALTH CARE; HEALTH CARE ASSOCIATED CANDIDEMIA; HOSPITAL PATIENT; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROBIOLOGY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPECIES DIFFERENTIATION; SPECIES DISTRIBUTION; TERTIARY HEALTH CARE;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; COMORBIDITY; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FEMALE; HOSPITALS; HUMANS; IOWA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84860723063     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.02.001     Document Type: Article

References (16)

1. Andes D.R., Safdar N., Baddley J. Impact of therapy on mortality across Candida spp in patients with invasive candidiasis from randomized clinical trials: a patient level analysis 2010.
2. Berrouane Y.F., Herwaldt L.A., Pfaller M.A. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999, 37:531-537.
3. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard - third edition, M27-A3 2008, CLSI, Wayne, PA.
4. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56:126-129.
5. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S.A., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37:1172-1177.
6. Hebert C., Villaran R., Tolentino J., Best L., Boonlayangoor S., Pitrak D., et al. Prior antimicrobial exposure and the risk of bloodstream infection with fluconazole-non-susceptible Candida strains. Scand J Infect Dis 2010, 42:506-509.
7. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. Antimicrobial resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
8. Malani A.N., Psarros G., Malani P.N., Kauffman C.A. Is age a risk factor for Candida glabrata colonization?. Mycoses 2011, 54:531-537.
9. Pappas P.G., Kauffmann C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the IDSA. Clin Infect Dis 2009, 48:503-535.
10. Pfaller M.A., Andes D., Diekema D.J., Espinel Ingroff A., Sheehan D. Wild type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Update 2010, 13:180-195.
11. Pfaller M.A., Boyken L., Hollis R., Kroeger J., Messer S., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156.
12. Pfaller M.A., Castanheira M., Lockhart S., Ahlquist A.M., Messer S., Jones R.N. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata: results from the SENTRY Antimicrobial Surveillance Program (2006-2010) and the Centers for Disease Control and Prevention population-based surveillance (2008-2010). J Clin Microbiol 2012, 50:1199-1203.
13. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Update 2011, 14:164-176.
14. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
15. Wey S.B., Mori M., Pfaller M.A., Woolson R.F., Wenzel R.P. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med 1988, 148:2642-2645.
16. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in U.S. hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317.